MMRF PRESS RELEASES
Kathy Giusti and MMRF Featured in Harvard Business Review
Recognized for accelerating research to improve treatment of multiple myeloma-
Norwalk, CT — June 7, 2011
The Multiple Myeloma Research Foundation (MMRF) today announced that the June issue of the Harvard Business Review features a profile of MMRF founder and CEO, Kathy Giusti, chronicling her journey from corporate leader in the pharmaceutical industry to nonprofit entrepreneur.
As described in the HBR article, Giusti, a graduate of Harvard Business School (HBS), who also recently addressed the HBS MBA Class of 2011 during the Class Day ceremonies, was diagnosed with multiple myeloma as a pharmaceutical executive at G.D. Searle. Following diagnosis, and upon discovering an empty and stalled new drug pipeline for multiple myeloma, she founded the Multiple Myeloma Research Foundation (MMRF) to apply innovative means to accelerate the development of new multiple myeloma treatments and effectively extend patient lives.
The article describes the impact MMRF has had in helping to advance four approved therapies for multiple myeloma in the past decade alone. It also highlights how the Multiple Myeloma Research Consortium (MMRC), founded in 2004, has helped to support the launch and rapid completion of more than 30 clinical trials of new and combination therapies, including eight now in late stage clinical development.
“I’m honored to have the opportunity to highlight through this publication the impressive efforts underway by researchers and the industry to effectively treat multiple myeloma,” said Giusti. “In the last 15 years, we have seen a vastly improved understanding of the disease and made great strides to increase the number of treatment options available to patients. While there is still much work to be done, I’m confident that patients will continue to benefit from new and targeted treatment options through the dedication of the multiple myeloma community, a collaborative approach to R&D, and the continued effort to build upon and leverage our biologic understanding of the disease.”
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States were estimated to be diagnosed with multiple myeloma and approximately 11,000 people died from the disease.
About the Multiple Myeloma Research Foundation (MMRF)
Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $165 million since its inception to fund nearly 120 laboratories worldwide, including 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 30 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donor’s investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.themmrf.org.
About the Multiple Myeloma Research Consortium
The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions. Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, H. Lee Moffitt Cancer Center & Research Institute, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University.
The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is a sister organization to the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in the today's most promising research areas in genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org.
Anne Quinn Young, MMRF
Kerry Littmann, Feinstein Kean Healthcare